Molecule Partner Indication China Ph3 / Pivotal Clinical Status
Planning Enrollment Global APAC
TherapeuticsEravacycline
(Xerava)
cIAI
NDA approved in US, EU, UKNDA approved in Singapore; NDA filed in China and Hong Kong
CABP
Phase 3-
NefeconlgA nephropathy
NDA approved in USNDA approved in US; Seek BLA approval based on US approval
EtrasimodUlcerative colitis
Phase 3South Korea and Taiwan included in multi-regional trial
Other autoimmune diseases
(CD, AD)
Phase 2/3(1)
RalinepagPAH
Phase 3
Taniborbactam
(VNRX-5133)
cUTI
Phase 3
FGF401HCC
Phase 1/2
XNW1011Renal disease
Phase 2
SPR206Gram negative infections
Phase 1
EDDC-2214COVID-19 oral antiviral treatments
Phase 1-
mRNA VaccinesPTX-COVID19-BCOVID-19
Phase 2/3
EVER-COVID19-M12nd generation COVID-19 booster
Pre-clinical-
Pre-clinical Candidate 1Infectious disease
Pre-clinical-
Pre-clinical Candidate 2Infectious disease
Pre-clinical-
Pre-clinical Candidate 3Infectious disease
Pre-clinical-

Abbreviations: HCC = hepatocellular carcinoma; CD = Crohn’s disease; AD = atopic dermatitis; IgA = immunoglobulin A; PAH = pulmonary arterial hypertension; cIAI = complicated intra-abdominal infections; cUTI = complicated urinary tract infections; IND = investigational new drug; BLA = biologics license application; NDA = new drug application; 
Notes: 
(1) Arena is conducting a Phase 2/3 program for CD and a Phase 2b program for AD.
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号